ライフサイエンスコーパス: radioligand

1 ET with [(11)C]MePPEP, a CB1 inverse agonist radioligand.

2 wly developed dopamine transporter (DAT) PET radioligand.

3 the radioligand and (S,S)-68 displacing the radioligand.

4 uman tissues with (125)I-GLP-1(7-36)NH2 as a radioligand.

5 nitrile ([11C]DASB), a serotonin transporter radioligand.

6 netic and binding characteristics of the new radioligand.

7 with (11)C-IMA107, a highly selective PDE10A radioligand.

8 sion was measured using (18)F-GE180 as a PET radioligand.

9 pharmacokinetic properties of the resulting radioligand.

10 hesus brain and binding specificity for this radioligand.

11 s was determined using (125)I-Tyr(4)-BN as a radioligand.

12 )Ser1,Leu8,D-Trp22,Tyr25]SS28} and its 111In radioligand.

13 l for analyzing data generated with this PET radioligand.

14 mor targeting are diagnostic and therapeutic radioligands.

15 rsibility than did previously reported MAO-B radioligands.

16 gress in the clinical development of tau PET radioligands.

17 endocrine tumors using somatostatin receptor radioligands.

18 ing the binding sites of high-affinity (14)C radioligands.

19 the healthy volunteer white matter for both radioligands.

20 gands; and sequential injection of different radioligands.

21 sitron emission tomography and TSPO-specific radioligands.

22 rospective clinical trials with several PSMA radioligands.

23 ting MS patients were studied using the TSPO radioligand (11)C-(R)-PK11195.

24 positron emission tomography with the novel radioligand (11)C-dihydroergotamine, which is chemically

25 The novel PET radioligand (11)C-LY2459989 displayed favorable pharmaco

26 or radioligand (11)C-NNC 112, and the 5-HT2A radioligand (11)C-MDL 100907 at 6 and 9 mo of age.

27 or radioligand (11)C-NNC 112, and the 5-HT2A radioligand (11)C-MDL 100907 at 6 and 9 mo of age.

28 PET and a novel high-affinity and selective radioligand (11)C-MK-8278, we studied the tracer biodist

29 gand (18)F-MNI-659, the dopamine D1 receptor radioligand (11)C-NNC 112, and the 5-HT2A radioligand (1

30 gand (18)F-MNI-659, the dopamine D1 receptor radioligand (11)C-NNC 112, and the 5-HT2A radioligand (1

31 resonance imaging and the recently developed radioligand (11)C-PBR28, we show increased brain levels

32 ls were imaged with the dopamine D2 receptor radioligand (11)C-raclopride, the PDE10A radioligand (18

33 ls were imaged with the dopamine D2 receptor radioligand (11)C-raclopride, the PDE10A radioligand (18

34 ing status, underwent PET scanning with TSPO radioligands ((11)C-PBR28 or (18)F-PBR111).

35 Here, PET with the radioligand [(11)C]-(+)-PHNO was used to quantify indivi

36 combining PET imaging with the D3-preferring radioligand [(11)C]-(+)-PHNO, pharmacology, a novel thre

37 n emission tomography (PET) imaging with the radioligand [(11)C]AZ10419369 administered as a bolus fo

38 with positron emission tomography, using the radioligand [(11)C]AZ10419369 for quantification of cere

39 nteers using the mu-opioid receptor-specific radioligand [(11)C]carfentanil three times, as follows:

40 n tomography scanning with the selective MOR radioligand [(11)C]carfentanil to test the hypothesis th

41 ssion tomography (PET) and the MOR-selective radioligand [(11)C]carfentanil.

42 a reduction in the binding of the DA D(2/3) radioligand [(11)C]FLB 457.

43 Using the radioligand [(11)C]OMAR and positron emission tomography

44 The authors used the second-generation radioligand [(11)C]PBR28 and PET to image microglial act

45 d 16 healthy controls using PET and the TSPO radioligand [(11)C]PBR28.

46 g agonist positron emission tomography (PET) radioligand [(11)C]PHNO with and without blockade with a

47 controls using PET and the D2/D3R-selective radioligand [(11)C]raclopride.

48 nd D2R availability using PET with selective radioligands [(11)C]carfentanil and [(11)C]raclopride, r

49 Using a newly developed and validated radioligand, [(11)C]IMA107, the authors report the first

50 Radioligand [111In-DOTA]LTT-SS28 showed good stability i

51 raphy scanning with the translocator protein radioligand 11C-PBR28 was performed at baseline.

52 s using the total distribution volume of the radioligand (18)F-3-fluoro-5-[(pyridin-3-yl)ethynyl]benz

53 vivo kinetics of the novel tau-specific PET radioligand (18)F-AV-1451 in cognitively healthy control

54 formed with the translocator protein-binding radioligand (18)F-GE180.

55 The novel radioligand (18)F-LY2459989 was synthesized by (18)F dis

56 tor radioligand (11)C-raclopride, the PDE10A radioligand (18)F-MNI-659, the dopamine D1 receptor radi

57 tor radioligand (11)C-raclopride, the PDE10A radioligand (18)F-MNI-659, the dopamine D1 receptor radi

58 efore, we recommend clinical transfer of the radioligand (18)F-PSMA-1007 for use as a diagnostic PET

59 The radioligand (18)F-PSMA-1007 was produced by a 2-step pro

60 dy uses the novel second-generation TSPO PET radioligand [(18)F]FEPPA to evaluate whether microglial

61 ith MS using the 18-kDa translocator protein radioligand [(18)F]PBR111.

62 g in vivo microPET imaging with a novel TSPO radioligand, (18)F-GE180, we detected significantly enha

63 n AD sections comparable to the tau-specific radioligand (3)H-T808; second, by very low nonspecific b

64 no group in 17 resulted in high affinity Y4R radioligands ([(3)H]-(2R,7R)-10, [(3)H]18) with subnanom

65 sed by their ability to displace orthosteric radioligand [(3)H]4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]t

66 n determined in competition with the agonist radioligand [(3)H]7-hydroxy-N,N-dipropyl-2-aminotetralin

67 erties of tool compounds for CB2R (e.g., the radioligand [(3)H]CP55,940) are not optimal, despite the

68 etralin (7-OH-DPAT) than with the antagonist radioligand [(3)H]N-methylspiperone.

69 s therefore demonstrate the development of a radioligand, [(3)H]LY2119620 to probe specifically the h

70 ranes in comparison with the standard GABAAR radioligand 4'-ethynyl-4-n-[(3)H]propylbicycloorthobenzo

71 ntroduction of small-molecule PSMA inhibitor radioligands, 40 y after the clinical introduction of (1

72 The GRPR antagonist radioligands (67)Ga-, (111)In-, and (177)Lu-NeoBOMB1, in

73 te-specific membrane antigen (PSMA)-targeted radioligand (68)Ga-PSMA-11 is regarded as a significant

74 stribution studies showed that injecting the radioligand 72 h after the administration of 5B1-TCO res

75 and rodent brains can be visualized with the radioligand 8-dicyclopropylmethyl-1-(11)C-methyl-3-propy

76 e describe the characterization of an M1 PAM radioligand, 8-((1S,2S)-2-hydroxycyclohexyl)-5-((6-(meth

77 nge with unlabeled ligand failed to diminish radioligand accumulation in brain tissue, due to the blo

78 In addition, radioligand accumulation was seen in primary tumor lesio

79 1R compounds, haloperidol, or BD1047, before radioligand administration, significantly attenuated (18

80 ety data were obtained during and 24 h after radioligand administration.

81 Using the cocktail of radioligands, all tumors without exception showed modera

82 In addition, the cocktail of radioligands always provided a homogeneous labeling of t

83 inding assay, with (R,R)-68 potentiating the radioligand and (S,S)-68 displacing the radioligand.

84 These suggestions were checked by radioligand and electrophysiology experiments, which con

85 etermined using [(125)I-Tyr(10)]GIP(1-30) as radioligand and GIP(1-30) as control peptide.

86 ed using LNCaP cells and ((125)I-BA)KuE as a radioligand and reference standard.

87 egions of interest were the striatum for all radioligands and additionally the striatum, rostral cort

88 g 18-kDa translocator protein (TSPO)-binding radioligands and PET.

89 utility and the development of tools such as radioligands and positron emission tomography tracers th

90 th [(11)C]CUMI-101, a 5-HT1A partial agonist radioligand, and functional magnetic resonance imaging o

91 eriments suggested Lu AE92686 as a promising radioligand, and the corresponding tritiated and (11)C-l

92 ecular targets; coinjection of a cocktail of radioligands; and sequential injection of different radi

93 heir peak, resulted in a brain uptake of the radioligand approximately 5-fold greater than baseline.

94 of neuroinflammation, most second-generation radioligands are sensitive to the single nucleotide poly

95 cision and without the need of high-affinity radioligands as surrogates.

96 cence-activated cell sorting analysis and by radioligand assay using (18)F-fallypride.

97 etabolite studies demonstrated 20% unchanged radioligand at 120 min after injection.

98 with a series of allosteric and orthosteric radioligands at structurally related CCK1R and CCK2R, as

99 a specific, selective, and high-affinity PET radioligand based on single-stranded DNA aptamer to addr

100 We performed radioligand-based uptake studies at chimeric constructs

101 adenosine receptor (AR) agonists) to enhance radioligand binding allosterically at the human dopamine

102 By using radioligand binding and bioluminescent resonance energy

103 binding configurations with a combination of radioligand binding and flux assays on wild-type and mut

104 e A1AR second extracellular loop (ECL2) with radioligand binding and functional interaction assays to

105 uch that endoplasmic reticulum export of and radioligand binding and substrate uptake by these DAT mu

106 localization and quantitative correlation of radioligand binding and tau antibody staining on the sam

107 ed mGlu5 receptor using a high-concentration radioligand binding assay enabled the identification of

108 mutagenesis and the scintillation proximity radioligand binding assay improved our understanding of

109 ies rationalized the results obtained in the radioligand binding assay.

110 ols 5a-f were pharmacologically evaluated in radioligand binding assays and some of them for their fu

111 with data from surface plasmon resonance and radioligand binding assays previously reported in the li

112 First, radioligand binding assays were performed to determine a

113 s of the novel compounds were assessed using radioligand binding assays, and the compounds with the h

114 In radioligand binding assays, EGF and TGFalpha exhibited i

115 Readouts are radioligand binding competition, arrestin recruitment, a

116 nositol 1,4,5-trisphosphate accumulation and radioligand binding experiments to determine the impact

117 Through kinetic radioligand binding experiments, we characterized mutant

118 panel of receptors/channels/transporters in radioligand binding experiments.

119 Radioligand binding indicated an intermediate-affinity i

120 Radioligand binding of compounds 11, 14, 15a, and 15c re

121 Radioligand binding studies and functional assays that u

122 Radioligand binding studies show a significant age-relat

123 ng of VUF11211 gave [(3)H]VUF11211, which in radioligand binding studies shows high affinity for CXCR

124 ist dissociation kinetics, and together with radioligand binding studies suggested a role for slow of

125 In radioligand binding studies, these compounds do not comp

126 physical interactions of both channels using radioligand binding studies.

127 by a combination of electrophysiological and radioligand binding studies.

128 void of tau pathology, excluding significant radioligand binding to any other central nervous system

129 Radioligand binding to brain homogenates revealed multip

130 scribe a novel method of kinetic analysis of radioligand binding to neuroreceptors in brain in vivo,

131 tion in brain tissue, due to the blocking of radioligand binding to plasma proteins that elevated the

132 2 adrenoceptors under condition of changing radioligand binding to plasma proteins.

133 o measure ligand-induced dimer formation and radioligand binding to study the effect of the ligands o

134 Interestingly, all three compounds inhibit radioligand binding to the prototypical MPEP/FPEB allost

135 Radioligand binding was blocked in a dose-dependent mann

136 g of only one radioligand was enhanced; SERT radioligand binding was minimally affected.

137 density in frontal cortex ([(3)H]-ketanserin radioligand binding).

138 HxR (x: 1-4) subtypes on Sf9 cell membranes (radioligand binding, [(35)S]GTPgammaS, or GTPase assays)

139 In silico docking experiments and radioligand binding-based reconstitution assays show hig

140 udy suggests that the use of a cocktail of 3 radioligands binding to somatostatin receptors, GLP-1 re

141 Radioligand-binding affinity cooperativity estimates wer

142 Using radioligand-binding and functional assays of inositol ph

143 Using radioligand-binding and functional assays, we posit that

144 nds have traditionally been characterized by radioligand-binding assays, which have low temporal and

145 based on systematic mutagenesis coupled to a radioligand-binding thermostability assay that can be ap

146 This radioligand bound specifically with high affinity within

147 08 was identified as the most promising I2BS radioligand candidate and radiolabeled with (11)C via me

148 d IMA106 were identified as potential PDE10A radioligand candidates and labeled with either (11)C via

149 In vitro screening with radioligand competition binding assays demonstrated vari

150 However, neither of the radioligands could be displaced by the 5-HT7 receptor se

151 lution, in vitro binding of the PD-sauvagine radioligand currently provides the most sensitive and ac

152 The resulting binding potentials of the radioligand declined by 50-60% in the presence of unlabe

153 First-in-human studies with PSMA radioligands derived from small-molecule PSMA inhibitors

154 n acceptable compromise between optimal PSMA radioligand design and a broad range of clinical demands

155 g site and are of interest for candidate PET radioligand development.

156 TSPO ligands that may serve as leads for PET radioligand development.

157 These were evaluated in a radioligand displacement binding assay, a [(35)S]GTPgamm

158 In [(3)H]N-methylscopolamine radioligand dissociation assays, approximately half of t

159 ly half of the 38 lead compounds altered the radioligand dissociation rate, a hallmark of allosteric

160 e section of tumor the binding with a single radioligand, either (125)I-Tyr(3)-octreotide, (125)I-GLP

161 The radioligand exhibited good in vivo stability and fast cl

162 nectin was labeled with (18)F to yield a PET radioligand for assessing PD-L1 expression in vivo.

163 hat [(18)F]8 is a promising PDE4B-preferring radioligand for clinical PET imaging.

164 ndicate that this allosteric inverse agonist radioligand for CXCR3 may facilitate the discovery, char

165 (18)F-FE-PE2I is clearly a suitable radioligand for DAT quantification and imaging of the ni

166 naphthoxazine ((11)C-(+)-PHNO) is an agonist radioligand for imaging dopamine D2 and D3 receptors in

167 F-tetrafluoroborate ((18)F-TFB), a novel PET radioligand for imaging the human sodium/iodide symporte

168 racteristics for (11)C-JNJ-54173717 as a PET radioligand for in vivo visualization of hP2X7R.

169 idinylethynyl)benzonitrile), a selective PET radioligand for mGluR5, and used it to quantify mGluR5 i

170 11)C-methyl-JNJ-31020028 the first candidate radioligand for PET investigations of NPY2 receptors in

171 ry found that (18)F-FIMX is an excellent PET radioligand for quantifying metabotropic glutamate recep

172 (18)F-FET-betaAG-TOCA a promising candidate radioligand for staging and management of NETs.

173 ha]pyrimi dine-3-yl)acetamide (DPA-714) is a radioligand for the 18-kDa translocator protein.

174 pane ((18)F-FE-PE2I) is a recently developed radioligand for the in vivo quantification of the dopami

175 (11)C-LY2795050 is a new antagonist PET radioligand for the kappa opioid receptor (KOR).

176 itrile ((18)F-FPEB) is a potent and specific radioligand for the metabotropic glutamate receptor subt

177 that the future development of any improved radioligand for TSPO should consider the possibility tha

178 ical potential of (68)Ga-NOTA-AE105 as a new radioligand for uPAR PET imaging in cancer patients.

179 ical potential of (68)Ga-NOTA-AE105 as a new radioligand for uPAR PET imaging in cancer patients.

180 at (18)F-fluorodeprenyl-D2 is a suitable PET radioligand for visualization of MAO-B activity in the h

181 None of the currently available PET radioligands for alpha7-nAChR are suitable for quantitat

182 uation questions the usefulness of universal radioligands for comparative binding studies.

183 al for ESR1-positive breast cancer and CXCR4 radioligands for ESR1-negative breast cancer.

184 tudy was to explore the application of GRP-R radioligands for imaging and therapy of BC by introducin

185 In order to discover improved radioligands for PET imaging, we explored structure-affi

186 New radioligands for positron emission tomography have gener

187 The specificity of all 3 radioligands for tau aggregates was supported, first, by

188 idity of novel (18)F-GE-179 and (18)F-GE-194 radioligands for the detection of changes in active NMDA

189 using positron emission tomography (PET) and radioligands for the translocator protein (TSPO), a mark

190 unlabeled ligand binding by the increase of radioligand free fractions in plasma.

191 eled JNJ-31020028 markedly displaced the PET radioligand from binding sites in the hippocampus, thala

192 , with the binding using a cocktail of all 3 radioligands, given concomitantly under identical experi

193 ntial affinity to almost all useful TSPO PET radioligands hampers such studies.

194 incidence and mortality of PC, the new PSMA radioligands have already had a remarkable impact on the

195 However, more recently developed agonist radioligands have shown enhanced sensitivity to endogeno

196 To date, no radioligands have shown well-validated efficacy for imag

197 (11)C-JNJ-42491293, a novel high-affinity radioligand (human 50% inhibitory concentration = 9.6 nM

198 Here, we quantified the (18)F-DPA-714 radioligand in healthy TSPO-genotyped volunteers and dev

199 ctivity, limiting its potential use as a PET radioligand in humans.

200 ing potential (receptor availability) of the radioligand in other regions.

201 as to evaluate the radiation exposure by the radioligand in PET imaging.

202 eins that elevated the free fractions of the radioligand in plasma.

203 ith the increase of the free fraction of the radioligand in plasma.

204 ost appropriate analysis method for this PET radioligand in this species.

205 We describe the kinetic behavior of the radioligand in vivo in humans.

206 The displacement of the radioligand in vivo was different in different receptor

207 After intravenous injection of the radioligands in Danish Landrace pigs, the in vivo brain

208 g (67/68)Ga-, (111)In-, and (177)Lu-NeoBOMB1 radioligands in GRPR-expressing cells and mouse models.

209 ydro-2H-indol-2-one) as selective 5-HT7R PET radioligands in the pig brain.

210 rience over the last 3 years using different radioligands indicates that PRLT is highly effective for

211 For the other scan, a constant radioligand infusion was applied for 95 min, during whic

212 ron emission tomography with a D2R-selective radioligand insensitive to endogenous dopamine, (N-[(11)

213 nsporters, and PET studies suggest that this radioligand is suitable for quantitative neuroimaging of

214 eting GRP-R-expressing BC tumors using GRP-R radioligands is promising for nuclear imaging and therap

215 A limitation of available agonist radioligands is that they incorporate the short-lived ra

216 nonspecific binding of the first-generation radioligand, low-resolution scanners, small sample sizes

217 cient amounts, in vivo imaging with a single radioligand may not always be successful.

218 ing to correct for individual differences in radioligand metabolism.

219 that imaging and therapy using GRPR or SSTR2 radioligands might especially be beneficial for ESR1-pos

220 breast cancer, targeting this receptor with radioligands might have a significant impact on staging

221 east cancer, targeting these receptors using radioligands might offer new imaging and therapeutic opp

222 e of heart disease, the emphasis has been on radioligands monitoring the norepinephrine pathway.

223 The 5-HT1A-specific antagonist radioligand N-{2-[4-(2-methoxyphenyl)piperazinyl]ethyl}-

224 using the D2R-selective and nondisplaceable radioligand (N-[(11)C]methyl)benperidol.

225 of general and efficient approaches to label radioligands necessary for drug discovery programs remai

226 labeling of the whole tumor, whereas single radioligands occasionally showed heterogeneous labeling.

227 rk describes development of a new antagonist radioligand of the type 1 cholecystokinin receptor (CCK1

228 as confirmed by both electron microscopy and radioligand receptor binding assays and shown to require

229 The radioligand (S,S)-(11)C-2-(alpha-(2-methoxyphenoxy)benzy

230 nt, 4-rate-constant model best described the radioligand's kinetics in normal gray matter of subjects

231 The development of a PET radioligand selective for I2-imidazoline binding sites (

232 (123)I-iodobenzovesamicol is a SPECT radioligand selective for the vesicular acetylcholine tr

233 n emission tomography and [(11)C]raclopride (radioligand sensitive to endogenous dopamine) to measure

234 he more reversible tracer kinetics, and this radioligand showed a dose-dependent decline in cerebral

235 All cobalt-labeled radioligands showed a high level of receptor-specific up

236 Both radioligands showed standard uptake values ranging from

237 lls and an IC50 of 16.4 nM for inhibition of radioligand stromal-derived factor-1alpha (SDF-1alpha) b

238 The radiosynthesis of both radioligands succeeded after optimization efforts (radio

239 ort the suitability of (11)C-GSK1482160 as a radioligand targeting P2X7R, a biomarker of neuroinflamm

240 ort the suitability of (11)C-GSK1482160 as a radioligand targeting P2X7R, a biomarker of neuroinflamm

241 Current PET radioligands targeting 5-HT1A receptors have limitations

242 In recent years, several radioligands targeting prostate-specific membrane antige

243 Imaging and therapy using radioligands targeting receptors overexpressed on tumor

244 PET radioligands targeting the 18-kDa translocator protein (

245 On the basis of a similar rationale, radioligands targeting the gastrin-releasing peptide rec

246 with in vitro methods whether a cocktail of radioligands targeting these 3 receptors would improve t

247 patient groups suited for the application of radioligands targeting these receptors.

248 We used [(18)F]FPEB, a radioligand that binds to the mGluR5, and positron emiss

249 A radioligand that could be used with PET to image and qua

250 (18)F-GE-179 is a novel radioligand that selectively binds to the open/active st

251 relationship study of a library of 25 novel radioligands that aims to identify radiotracers with opt

252 neuroimaging has been limited by the lack of radioligands that are selective for noradrenergic neurot

253 dvance in positron emission tomography (PET) radioligands that bind to the translocator protein (TSPO

254 Recently, second-generation PET radioligands that can reveal the extent of microglial ac

255 ve been learned regarding the design of PSMA radioligands that have already been developed?

256 d molecular radiotherapy using PSMA-targeted radioligand therapy (PRLT) with (177)Lu-PSMA ligands.

257 Clinical (177)Lu-PSMA-617 radioligand therapy (RLT) is applied in advanced-stage p

258 617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic ca

259 Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of PSMA is a

260 Radioligand therapy (RLT) with (177)Lu-PSMA-617 (PSMA is

261 Fifty-six mCRPC patients underwent PSMA radioligand therapy (RLT) with (177)Lu-PSMA.

262 based PSMA ligands used for both imaging and radioligand therapy are the mainstays of the current suc

263 The use of (177)Lu-PSMA-based radioligand therapy has demonstrated a reasonable respon

264 ospective multicenter analysis suggests that radioligand therapy with (177)Lu-PSMA-617 is safe and we

265 is an effective and promising candidate for radioligand therapy, with a favorable preliminary safety

266 ven the high level of safety of (177)Lu-PSMA radioligand therapy, with only minimal grade 3 and 4 tox

267 promising target for diagnostic imaging and radioligand therapy.

268 etastatic castration-resistant PC after PSMA radioligand therapy.

269 script allows specific receptor binding of a radioligand to be quantified without injecting pharmacol

270 directly established for lack of a suitable radioligand to localize the binding site.

271 hat is based on binding of an (125)I-labeled radioligand to the unpurified, detergent-solubilized MP.

272 ding of a positron emission tomography (PET) radioligand to the vesicular monoamine transporter 2, (V

273 eric site positron emission tomography (PET) radioligands to assess receptor occupancy in the brain.

274 , and the inability of targeted adrenoceptor radioligands to have an impact on clinical care of heart

275 of the saturable binding of a benzodiazepine radioligand, unlike other small molecule antagonists and

276 TSPO radioligand uptake was increased in the brains of MS pat

277 ualize Abeta plaque load for comparison with radioligand uptake.

278 nd (S,S)-68 have differential effects on the radioligand used for the binding assay, with (R,R)-68 po

279 erocyclic positron emission tomography (PET) radioligands using the copper-mediated (18)F-fluorinatio

280 igands was enhanced; NET binding of only one radioligand was enhanced; SERT radioligand binding was m

281 Over 60% parent radioligand was present in plasma at 60 min.

282 In all species, specific binding of the radioligand was seen in the striatum but not in the cere

283 modified with TCO, and a novel NOTA-PEG7-Tz radioligand was synthesized with the goal of improving o

284 , the binding of two structurally dissimilar radioligands was enhanced; NET binding of only one radio

285 Ex vivo brain autoradiography of radioligands was performed at subacute (5-6 d) and chron

286 n of (67)Ga-, (111)In-, and (177)Lu-NeoBOMB1 radioligands was studied in PC-3 cells at 37 degrees C,

287 ding potentials of NPY2 receptors toward the radioligand were calculated using the simplified referen

288 etargeting approach was optimized, and the 2 radioligands were compared using biodistribution and PET

289 enoceptor drugs were radiolabeled and potent radioligands were prepared in order to image the beta-ad

290 Both radioligands were specific for 5-HT7R, as binding could

291 fluoromisonidazole, two well-established PET radioligands, were assessed for their potential to image

292 s, [(18)F]3 is the first (18)F-labeled mGlu4 radioligand, which can be further modified to improve ph

293 y for allosteric modulators with orthosteric radioligands, which has so far been the most applied app

294 sualized P2X7R in the monkey brain, and this radioligand will be further evaluated in a clinical sett

295 These radioligands will be useful for characterizing the drug-

296 Whereas early studies using a radioligand with low signal-to-noise in small samples sh

297 To our knowledge, there is no other radioligand with these favorable properties and with thi

298 Radioligands with PET accurately quantify TSPO in neuroi

299 Thus, the new radioligand would likely have greater sensitivity in det

300 ecific 5-HT1A binding exhibited retention of radioligand, yielding SUVs of 0.4-0.9 at 120 min.